FDC of Piperacillin and Tazobactam

## Report on Medicinal Product Label Change Regarding Piperacillin and Tazobactam **1. Executive Summary:** This report analyzes a communication from the Drugs Controller General of India (DCGI) regarding a label change for medicinal products containing Piperacillin and Tazobactam. The core purpose of this communication, as inferred from the text, is to address reported incidents related to bronchospasm associated with these products. This report details the key aspects of this communication, focusing on the directive for label changes and its likely implications for pharmaceutical companies and patients. **2. Introduction:** This report provides an informative analysis of a communication issued by the Office of Drugs Controller General India (DCGI) concerning label changes for medicinal products containing Piperacillin and Tazobactam. The analysis is based solely on the provided text and aims to inform the affected industry of the implications of this directive. **3. Policy Overview:** This document appears to be a directive related to an existing policy or regulation concerning drug safety and labeling. * **Core Objective(s) (inferred):** The core objective is to mitigate potential risks associated with the use of Piperacillin and Tazobactam, specifically related to bronchospasm, by ensuring adequate warning information is present on the product labels. This suggests a patient safety focus. **4. Background and Rationale:** Based on the text, the rationale for this communication is the reported incidence of bronchospasm associated with medicinal products containing Piperacillin and Tazobactam. This indicates that there may be a need to update product labels to reflect this risk adequately, ensuring that healthcare professionals and patients are aware of the potential adverse effect. The communication serves as a proactive measure to address potential safety concerns and improve patient outcomes. **5. Key Provisions / Changes:** This document functions as an amendment. * **Specific part of the original policy being changed:** The communication directly affects the labeling requirements for medicinal products containing Piperacillin and Tazobactam. While the exact pre-existing policy is not stated, this communication requires a modification of the existing label. * **New rule/provision:** The "new" rule/provision mandates a label change for medicinal products containing Piperacillin and Tazobactam to address the risk of bronchospasm. The specific wording of the label change is not provided in the text but is strongly implied. * **Difference/effect of this change:** The change aims to ensure that patients and healthcare professionals are aware of the potential for bronchospasm when using these products. This awareness may lead to earlier detection and treatment of this adverse effect, potentially reducing morbidity. It could also lead to more cautious use of these medications in susceptible individuals. **6. Target Audience and Stakeholders:** The primary target audience includes: * **Pharmaceutical companies** manufacturing and marketing medicinal products containing Piperacillin and Tazobactam, as they are directly responsible for implementing the label changes. * **State/UT Drugs Controllers**, who are responsible for ensuring compliance with the labeling requirements within their jurisdictions. * **Healthcare Professionals**, who need to be aware of the updated labeling and the potential for bronchospasm when prescribing or administering these products. * **Patients** who use these medications. Other stakeholders include Drug Manufacturing Associations like IDMA, OPPI, IPACI, and FOPE. **7. Implementation Aspects (Inferred):** * **Responsible agency/bodies:** The Directorate General of Health Services, specifically the Office of Drugs Controller General India (DCGI), is responsible for issuing and overseeing the implementation of this directive. State/UT Drugs Controllers are responsible for local enforcement. * **Timelines or procedures:** The text does not specify exact timelines or procedures for implementation. However, the urgent nature of the communication suggests that the label changes should be implemented promptly. It is likely that further guidance on the specifics of the label changes (e.g., the exact wording of the warning) will be provided separately, but no mention of this is in the provided text. The mention of a review meeting also suggests some internal assessment of the application. * **Amendment Specifics:** The manufacturers must modify labels, and the regulatory bodies must verify compliance. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome of these specific changes is: * Increased awareness among healthcare professionals and patients regarding the potential for bronchospasm associated with Piperacillin and Tazobactam. * Improved patient safety through earlier detection and management of bronchospasm. * Potentially more cautious use of these products in patients with a history of respiratory problems or other risk factors for bronchospasm. **9. Conclusion:** The communication from the DCGI regarding label changes for medicinal products containing Piperacillin and Tazobactam is a significant directive aimed at improving patient safety. By addressing the reported incidence of bronchospasm and mandating label modifications, the DCGI seeks to ensure that healthcare professionals and patients are adequately informed about the potential risks associated with these medications. Pharmaceutical companies must take immediate steps to implement the required label changes and ensure compliance with the directive. The significance of this amendment lies in its potential to mitigate risks and improve patient outcomes.

Key Entities Referenced